202 related articles for article (PubMed ID: 27339837)
1. Inhibitor development in previously untreated patients with severe haemophilia A: a nationwide multicentre study in Finland.
Vepsäläinen K; Lassila R; Arola M; Huttunen P; Koskinen S; Ljung R; Lähteenmäki P; Möttönen M; Riikonen P
Haemophilia; 2016 Sep; 22(5):721-9. PubMed ID: 27339837
[TBL] [Abstract][Full Text] [Related]
2. Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010.
Vézina C; Carcao M; Infante-Rivard C; Lillicrap D; Stain AM; Paradis E; Teitel J; Rivard GE;
Haemophilia; 2014 Nov; 20(6):771-6. PubMed ID: 25039669
[TBL] [Abstract][Full Text] [Related]
3. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.
Ljung R; Kenet G; Mancuso ME; Kaleva V; Rusen L; Tseneklidou-Stoeter D; Michaels LA; Shah A; Hong W; Maas Enriquez M;
Haemophilia; 2016 May; 22(3):354-60. PubMed ID: 26663410
[TBL] [Abstract][Full Text] [Related]
4. Joint bleeds increase the inhibitor response to human factor VIII in a rat model of severe haemophilia A.
Lövgren KM; Søndergaard H; Skov S; Wiinberg B
Haemophilia; 2016 Sep; 22(5):772-9. PubMed ID: 27439658
[TBL] [Abstract][Full Text] [Related]
5. Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study.
Liesner RJ; Abraham A; Altisent C; Belletrutti MJ; Carcao M; Carvalho M; Chambost H; Chan AKC; Dubey L; Ducore J; Gattens M; Gresele P; Gruel Y; Guillet B; Jimenez-Yuste V; Kitanovski L; Klukowska A; Lohade S; Mancuso ME; Oldenburg J; Pavlova A; Pollio B; Sigaud M; Vdovin V; Vilchevska K; Wu JKM; Jansen M; Belyanskaya L; Walter O; Knaub S; Neufeld EJ
Thromb Haemost; 2021 Nov; 121(11):1400-1408. PubMed ID: 33581698
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A.
Meunier S; Alamelu J; Ehrenforth S; Hanabusa H; Abdul Karim F; Kavakli K; Khodaie M; Staber J; Stasyshyn O; Yee DL; Rageliene L
Thromb Haemost; 2017 Aug; 117(9):1705-1713. PubMed ID: 28692108
[TBL] [Abstract][Full Text] [Related]
7. Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A.
Mancuso ME; Mannucci PM; Rocino A; Garagiola I; Tagliaferri A; Santagostino E
J Thromb Haemost; 2012 May; 10(5):781-90. PubMed ID: 22452823
[TBL] [Abstract][Full Text] [Related]
8. Prophylaxis vs. on-demand treatment with Nuwiq(®) (Human-cl rhFVIII) in adults with severe haemophilia A.
Tiede A; Oldenburg J; Lissitchkov T; Knaub S; Bichler J; Manco-Johnson MJ
Haemophilia; 2016 May; 22(3):374-80. PubMed ID: 26582282
[TBL] [Abstract][Full Text] [Related]
9. Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study.
Scott MJ; Xiang H; Hart DP; Palmer B; Collins PW; Stephensen D; Sima CS; Hay CRM
Haemophilia; 2019 Mar; 25(2):205-212. PubMed ID: 30408835
[TBL] [Abstract][Full Text] [Related]
10. Long-term clinical and economic outcomes in previously untreated paediatric patients with severe haemophilia A: A nationwide real-world study with 700 person-years.
Vepsäläinen K; Riikonen P; Lassila R; Arola M; Huttunen P; Lähteenmäki P; Möttönen M; Selander T; Martikainen J
Haemophilia; 2018 May; 24(3):436-444. PubMed ID: 29493848
[TBL] [Abstract][Full Text] [Related]
11. Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study.
Schobess R; Kurnik K; Friedrichs F; Halimeh S; Krümpel A; Bidlingmaier C; Nowak-Göttl U
Thromb Haemost; 2008 Jan; 99(1):71-6. PubMed ID: 18217137
[TBL] [Abstract][Full Text] [Related]
12. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development.
Kurnik K; Bidlingmaier C; Engl W; Chehadeh H; Reipert B; Auerswald G
Haemophilia; 2010 Mar; 16(2):256-62. PubMed ID: 19878331
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting.
Musso R; Santagostino E; Faradji A; Iorio A; van der Meer J; Ingerslev J; Lambert T; Maas-Enriquez M; Gorina E;
Thromb Haemost; 2008 Jan; 99(1):52-8. PubMed ID: 18217134
[TBL] [Abstract][Full Text] [Related]
14. Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review.
Hassan S; Cannavò A; Gouw SC; Rosendaal FR; van der Bom JG
J Thromb Haemost; 2018 Jun; 16(6):1055-1068. PubMed ID: 29665204
[TBL] [Abstract][Full Text] [Related]
15. Inhibitor development in two cousins receiving full-length factor VIII (FVIII) and FVIII-Fc fusion protein.
Ragni MV; Alabek M; Malec LM
Haemophilia; 2016 Sep; 22(5):e462-4. PubMed ID: 27501368
[No Abstract] [Full Text] [Related]
16. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A.
Smith MP; Giangrande P; Pollman H; Littlewood R; Kollmer C; Feingold J;
Haemophilia; 2005 Sep; 11(5):444-51. PubMed ID: 16128886
[TBL] [Abstract][Full Text] [Related]
17. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis.
Peyvandi F; Cannavò A; Garagiola I; Palla R; Mannucci PM; Rosendaal FR;
J Thromb Haemost; 2018 Jan; 16(1):39-43. PubMed ID: 29080391
[TBL] [Abstract][Full Text] [Related]
18. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis.
Valentino LA; Pipe SW; Collins PW; Blanchette VS; Berntorp E; Fischer K; Ewenstein BM; Oh M; Spotts G
Haemophilia; 2016 Jul; 22(4):514-20. PubMed ID: 26930418
[TBL] [Abstract][Full Text] [Related]
19. Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis.
Marcucci M; Mancuso ME; Santagostino E; Kenet G; Elalfy M; Holzhauer S; Bidlingmaier C; Escuriola Ettingshausen C; Iorio A; Nowak-Göttl U
Thromb Haemost; 2015 May; 113(5):958-67. PubMed ID: 25631402
[TBL] [Abstract][Full Text] [Related]
20. Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients.
Epstein J; Xiong Y; Woo P; Li-McLeod J; Spotts G
Haemophilia; 2012 Mar; 18(2):187-92. PubMed ID: 21883704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
